By ,
Published November 18, 2016
Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration rejected the drugmaker's bladder cancer treatment.
The company said it was considering a new smaller study for the drug, apaziquone, that would replace the ongoing late-stage study in which patient enrolment has been stopped.
https://www.foxnews.com/health/spectrum-pharma-says-fda-rejects-its-bladder-cancer-drug